Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00680056
Recruitment Status : Completed
First Posted : May 19, 2008
Results First Posted : December 3, 2009
Last Update Posted : January 20, 2010
Information provided by:
Federal University of São Paulo

Brief Summary:
The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d. via Aeroliser) and combined with a long-acting anti-cholinergic (tiotropium bromide 18µg o.d via Handihaler) on breathlessness, dynamic hyperinflation and exercise tolerance in patients with advanced, but stable, chronic obstructive pulmonary disease. The study hypothesis is that combining long acting bronchodilators with different action mechanisms would promote synergistic effects on clinical outcomes.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Chronic Bronchitis Pulmonary Emphysema Drug: Formoterol plus Placebo (Tiotropium) Drug: Formoterol plus Tiotropium Phase 4

Detailed Description:
This will be a single center, randomized, double-blind study consisting of two 2-week treatment periods separated by a 5-7 days washout phase without long-acting bronchodilators. Eligible patients who complete the one week screening phase will be randomized to one of two treatment sequences: 1) Formoterol --> Formoterol + Tiotropium or 2) Formoterol + Tiotropium --> Formoterol. During the treatment periods, patients will be allowed to use a short-acting beta2-adrenergic+short-acting anticholinergic as rescue medication (salbutamol+ipratropium via MDI)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients
Study Start Date : November 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Active Comparator: 1
Formoterol plus Placebo (Tiotropium)
Drug: Formoterol plus Placebo (Tiotropium)
Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
Experimental: 2
Formoterol plus Tiotropium
Drug: Formoterol plus Tiotropium
Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.

Primary Outcome Measures :
  1. Percentage Change in Exercise Tolerance From Baseline at 2 Weeks [ Time Frame: Baseline and after 2 weeks with each treatment ]

Secondary Outcome Measures :
  1. Mean Score on the Transitional Dyspnea Index (TDI) [ Time Frame: After 2 week of each treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • COPD patients aged ≥ 40 years with stable moderate-to-severe airflow obstruction (FEV1 < 70% and FEV1/FVC ≤ 70% of predicted normal value) post-bronchodilator
  • presenting with a long history of smoking (> 20 pack-years) and chronic breathlessness (Baseline Dyspnoea Index total score < 9)

Exclusion Criteria:

  • significant cardiovascular disease, hospitalization for COPD exacerbation or presence of a respiratory tract infection within 1 month of screening
  • current or childhood asthma
  • a history of allergic rhinitis or other atopic disease
  • inability to interrupt usual bronchodilator medication
  • use of oral steroids within a month before screening
  • need for long-term oxygen therapy, arterial oxygen saturation < 85% at rest anemia, hypo- and hyperthyroidism, hyperadrenergic state
  • uncontrolled insulin dependent diabetes mellitus, malignancy, or any disease or condition which limits exercise performance other than COPD
  • change in inhaled corticosteroid or theophylline use within 1 month prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00680056

Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE)
Sao Paulo, Brazil, 04020-050
Sponsors and Collaborators
Federal University of São Paulo
Principal Investigator: J Alberto Neder, MD, phD Federal University of Sao Paulo

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: J Alberto Neder, Federal University of Sao Paulo Identifier: NCT00680056     History of Changes
Other Study ID Numbers: TIOFOR
First Posted: May 19, 2008    Key Record Dates
Results First Posted: December 3, 2009
Last Update Posted: January 20, 2010
Last Verified: October 2009

Keywords provided by Federal University of São Paulo:
Pulmonary Disease, Chronic Obstructive
Bronchodilator Agents
Exercise Tolerance
Randomized Controlled Trial [Publication Type]

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Bronchitis, Chronic
Pulmonary Emphysema
Respiratory Tract Diseases
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Bronchial Diseases
Respiratory Tract Infections
Formoterol Fumarate
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Cholinergic Agents